OBJECTIVES: The aim of this study was to assess the relationship between sex hormones and natriuretic peptide levels in community-based adults. BACKGROUND: Women have higher circulating natriuretic peptide concentrations than men, but the mechanisms for these sex-related differences and the impact of hormone therapy are unclear. Experimental studies suggest that androgens may suppress natriuretic peptide secretion. METHODS: We measured N-terminal pro-B-type natriuretic peptide (NT-proBNP), total testosterone, and sex hormone-binding globulin plasma levels in 4,056 men and women (mean age 40 ± 9 years) from the Framingham Heart Study Third-Generation cohort. Sex/hormone status was grouped as: 1) men; 2) post-menopausal women not receiving hormone replacement therapy; 3) pre-menopausal women not receiving hormonal contraceptives; 4) post-menopausal women receiving hormone replacement therapy; and 5) pre-menopausal women receiving hormonal contraceptives. RESULTS: Circulating NT-proBNP levels were associated with sex/hormone status (overall p < 0.0001). Men had lower NT-proBNP levels than women of all menopause or hormone groups, and women receiving hormonal contraceptives had higher NT-proBNP levels than women who were not receiving hormone therapy (all p < 0.0001). These relationships remained significant after adjusting for age, body mass index, and cardiovascular risk factors. Across sex/hormone status groups, free testosterone (FT) levels decreased and sex hormone-binding globulin levels increased in tandem with increasing NT-proBNP levels. In sex-specific analyses, NT-proBNP levels decreased across increasing quartiles of FT in men (p for trend <0.01) and women (p for trend <0.0001). Adjustment for FT markedly attenuated the association between sex/hormone status and NT-proBNP concentrations. CONCLUSIONS: These findings suggest that lower levels of circulating androgens and the potentiating effect of exogenous female hormone therapy contribute to the higher circulating NT-proBNP concentrations in women.
OBJECTIVES: The aim of this study was to assess the relationship between sex hormones and natriuretic peptide levels in community-based adults. BACKGROUND:Women have higher circulating natriuretic peptide concentrations than men, but the mechanisms for these sex-related differences and the impact of hormone therapy are unclear. Experimental studies suggest that androgens may suppress natriuretic peptide secretion. METHODS: We measured N-terminal pro-B-type natriuretic peptide (NT-proBNP), total testosterone, and sex hormone-binding globulin plasma levels in 4,056 men and women (mean age 40 ± 9 years) from the Framingham Heart Study Third-Generation cohort. Sex/hormone status was grouped as: 1) men; 2) post-menopausal women not receiving hormone replacement therapy; 3) pre-menopausal women not receiving hormonal contraceptives; 4) post-menopausal women receiving hormone replacement therapy; and 5) pre-menopausal women receiving hormonal contraceptives. RESULTS: Circulating NT-proBNP levels were associated with sex/hormone status (overall p < 0.0001). Men had lower NT-proBNP levels than women of all menopause or hormone groups, and women receiving hormonal contraceptives had higher NT-proBNP levels than women who were not receiving hormone therapy (all p < 0.0001). These relationships remained significant after adjusting for age, body mass index, and cardiovascular risk factors. Across sex/hormone status groups, free testosterone (FT) levels decreased and sex hormone-binding globulin levels increased in tandem with increasing NT-proBNP levels. In sex-specific analyses, NT-proBNP levels decreased across increasing quartiles of FT in men (p for trend <0.01) and women (p for trend <0.0001). Adjustment for FT markedly attenuated the association between sex/hormone status and NT-proBNP concentrations. CONCLUSIONS: These findings suggest that lower levels of circulating androgens and the potentiating effect of exogenous female hormone therapy contribute to the higher circulating NT-proBNP concentrations in women.
Authors: Christina Wang; Steve Shiraishi; Andrew Leung; Sima Baravarian; Laura Hull; Victor Goh; Paul W N Lee; Ronald S Swerdloff Journal: Steroids Date: 2008-05-21 Impact factor: 2.668
Authors: Amiram Nir; Angelika Lindinger; Manfred Rauh; Benjamin Bar-Oz; Stephanie Laer; Lynn Schwachtgen; Andreas Koch; Jan Falkenberg; Thomas S Mir Journal: Pediatr Cardiol Date: 2008-07-04 Impact factor: 1.655
Authors: Navin Suthahar; Wouter C Meijers; Jennifer E Ho; Ron T Gansevoort; Adriaan A Voors; Peter van der Meer; Stephan J L Bakker; Stephane Heymans; Vanessa van Empel; Blanche Schroen; Pim van der Harst; Dirk J van Veldhuisen; Rudolf A de Boer Journal: Eur J Heart Fail Date: 2018-06-01 Impact factor: 15.534
Authors: Emily S Lau; Samantha M Paniagua; James Sawalla Guseh; Vijeta Bhambhani; Markella V Zanni; Paul Courchesne; Asya Lyass; Martin G Larson; Daniel Levy; Jennifer E Ho Journal: J Am Coll Cardiol Date: 2019-09-24 Impact factor: 24.094
Authors: Wendy Ying; Di Zhao; Pamela Ouyang; Vinita Subramanya; Dhananjay Vaidya; Chiadi E Ndumele; Kavita Sharma; Sanjiv J Shah; Susan R Heckbert; Joao A Lima; Christopher R deFilippi; Matthew J Budoff; Wendy S Post; Erin D Michos Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Zhuo Zhao; Hao Wang; Jewell A Jessup; Sarah H Lindsey; Mark C Chappell; Leanne Groban Journal: Am J Physiol Heart Circ Physiol Date: 2014-01-10 Impact factor: 4.733
Authors: Jared W Magnani; Carlee B Moser; Joanne M Murabito; Lisa M Sullivan; Na Wang; Patrick T Ellinor; Ramachandran S Vasan; Emelia J Benjamin; Andrea D Coviello Journal: Circ Arrhythm Electrophysiol Date: 2014-03-08
Authors: S Jeson Sangaralingham; Paul M McKie; Tomoko Ichiki; Christopher G Scott; Denise M Heublein; Horng H Chen; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett Journal: Hypertension Date: 2015-04-20 Impact factor: 10.190
Authors: Eleanor Lin; Elizabeth McCabe; Christopher Newton-Cheh; Kenneth Bloch; Emmanuel Buys; Thomas Wang; Karen K Miller Journal: Fertil Steril Date: 2011-12-02 Impact factor: 7.329